Literatur
- 1
Bug G, Ritter M, Wassmann B. et al .
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk
acute myeloid leukemia.
Cancer.
2005;
104
2717-2725
- 2
Fiedler W, Serve H, Dohner H. et al .
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant
acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood.
2005;
105
986-993
- 3
Hiddemann W, Spiekermann K, Buske C. et al .
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Crit Rev Oncol Hematol.
2005;
56
235-245
- 4
Kuendgen A, Schmid M, Schlenk R. et al .
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination
with all-trans retinoic acid in patients with acute myeloid leukemia.
Cancer.
2006;
106
112-119
- 5
Kuendgen A, Strupp C, Aivado M. et al .
Treatment of myelodysplastic syndromes with valproic acid alone or in combination
with all-trans retinoic acid.
Blood.
2004;
104
1266-1269
- 6
Schmid C, Schleuning M, Schwerdtfeger R. et al .
Long term survival in refractory acute myeloid leukemia after sequential treatment
with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation.
Blood.
2006;
DOI 10.1182 [Online-Vorabpublikation]
- 7
Smith B D, Levis M, Beran M. et al .
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity
in patients with relapsed or refractory acute myeloid leukemia.
Blood.
2004;
103
3669-3676
- 8
Spiekermann K, Hiddemann W.
Molekulare Zielstrukturen in der Onkologie.
Internist (Berl).
2005;
46
847-860
- 9
Stone R M, DeAngelo D J, Klimek K. et al .
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to
a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood.
2005;
105
54-60
- 10
Tallman M S.
New agents for the treatment of acute myeloid leukemia.
Best Pract Res Clin Haematol.
2006;
19
311-320
Prof. Dr. W. Hiddemann
Medizinische Klinik und Poliklinik III, Klinikum der Universität München - Großhadern
Marchioninistraße 15
81377 München
Phone: 089/70952551
Fax: 089/70952550
Email: sekrmed3@med.uni-muenchen.de
